Key facts
- It has raised $6.4M across 2 recorded rounds; the latest was Seed Round ($500K) in Sep 2024.
- Notable investors include Alumni Ventures, SOSV, IndieBio, E14 Fund, Asymmetry Ventures — 15 tracked in total.
- Capra Biosciences has filed 3 Form Ds with the SEC since 2022, most recently Oct 2024 ($500K sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Capra Biosciences
Funding rounds
2 roundsAbout Capra Biosciences
Operator of a bioreactor platform intended to make a way to produce bio-based chemicals. The company's platform can reduce the downstream processing requirements and costs inherent in the bio-manufacturing of products such as fuels, enabling clients to produce hydrophobic products like retinol and performance lubricants.
- Sector
- Materials and Resources
- HQ
- Sterling, VA, United States
- Founded
- 2020
- Employees
- 20
- Website
- caprabiosciences.com/
- Ownership
- Privately Held (backing)
Capra Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Capra Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Capra Biosciences in its N-PORT filings yet. We sweep new filings monthly.